You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 11, 2025

ZEGERID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ZEGERID?
  • What are the global sales for ZEGERID?
  • What is Average Wholesale Price for ZEGERID?
Summary for ZEGERID
Drug patent expirations by year for ZEGERID
Drug Prices for ZEGERID

See drug prices for ZEGERID

Recent Clinical Trials for ZEGERID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Syndax PharmaceuticalsPhase 1
Population Health Research InstitutePhase 3
NorginePhase 3

See all ZEGERID clinical trials

Paragraph IV (Patent) Challenges for ZEGERID
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZEGERID Powder for Oral Suspension omeprazole; sodium bicarbonate 20mg/1680mg per packet 021636 1 2007-11-13
ZEGERID Powder for Oral Suspension omeprazole; sodium bicarbonate 40 mg/1680 mg per packet 021636 1 2007-08-24
ZEGERID Capsules omeprazole; sodium bicarbonate 20 mg/1100 mg and 40 mg/1100 mg 021849 1 2007-04-30

US Patents and Regulatory Information for ZEGERID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix ZEGERID omeprazole; sodium bicarbonate CAPSULE;ORAL 021849-001 Feb 27, 2006 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Riley Consumer ZEGERID OTC omeprazole; sodium bicarbonate CAPSULE;ORAL 022281-001 Dec 1, 2009 OTC Yes Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Riley Consumer ZEGERID OTC omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 022283-001 Jun 17, 2013 OTC Yes Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate CAPSULE;ORAL 021849-002 Feb 27, 2006 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZEGERID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 6,699,885 ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 6,489,346 ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate CAPSULE;ORAL 021849-002 Feb 27, 2006 6,699,885 ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-002 Dec 21, 2004 7,399,772 ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 RE45198 ⤷  Get Started Free
Salix ZEGERID omeprazole; sodium bicarbonate FOR SUSPENSION;ORAL 021636-001 Jun 15, 2004 6,699,885 ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZEGERID

See the table below for patents covering ZEGERID around the world.

Country Patent Number Title Estimated Expiration
Norway 331542 ⤷  Get Started Free
Spain 2275650 ⤷  Get Started Free
Russian Federation 2279276 НОВЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ ЗАМЕЩЕННЫХ БЕНЗИМИДАЗОЛОВ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ (NEW MEDICINAL FORMULATIONS OF SUBSTITUTED BENZIMIDAZOLES AND METHOD FOR THEIR USING) ⤷  Get Started Free
Australia 2005229686 ⤷  Get Started Free
European Patent Office 1414452 ⤷  Get Started Free
Russian Federation 2002121623 ⤷  Get Started Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZEGERID

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1499331 122014000007 Germany ⤷  Get Started Free PRODUCT NAME: NATRIUMSULFAT, MAGNESIUMSULFAT UND KALIUMSULFAT; NAT. REGISTRATION NO/DATE: 86203.00.00 20130808; FIRST REGISTRATION: BELGIEN BE434323 20130220
1020461 C300482 Netherlands ⤷  Get Started Free PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
0984957 2012/048 Ireland ⤷  Get Started Free PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1499331 SPC/GB13/034 United Kingdom ⤷  Get Started Free PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0984957 122012000017 Germany ⤷  Get Started Free PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
1020461 300482 Netherlands ⤷  Get Started Free PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for ZEGERID

Last updated: July 27, 2025


Introduction

ZEGERID, a proton pump inhibitor (PPI) formulated as a capsule combining omeprazole and sodium bicarbonate, has maintained a significant presence in the gastric acid suppression market since its FDA approval in 2003. Its unique formulation, offering rapid onset and sustained acid suppression, positions it within the competitive landscape of OTC and prescription therapies targeting gastroesophageal reflux disease (GERD), peptic ulcers, and related acid-related disorders. This analysis explores the evolving market conditions, revenue streams, competitive dynamics, regulatory influences, and future prospects shaping ZEGERID’s financial trajectory.


Market Overview and Demand Drivers

The global gastroesophageal reflux disease (GERD) therapeutics market was valued at approximately USD 8.3 billion in 2022 and is projected to grow at a CAGR of around 4–5% through 2030, driven by increasing prevalence, aging populations, and lifestyle factors (Source: Grand View Research). ZEGERID, leveraging its OTC and prescription formulations, targets key segments within this expanding market.

Key demand drivers include:

  • Rising GERD prevalence: An estimated 20–30% of Western populations experience GERD symptoms regularly. The condition’s chronic nature encourages long-term medication use.
  • Shift toward over-the-counter (OTC) options: Regulatory approvals enabling OTC availability bolster sales volume and accessibility, particularly in developed markets.
  • Growing awareness of acid-related disorders: Patient education campaigns and doctor-patient dialogues increase diagnosis and medication adherence.
  • Reimbursement and healthcare policies: Reimbursement models favor cost-effective OTC options, reducing healthcare system burdens.

Market Dynamics Influencing ZEGERID

Competitive Landscape

ZEGERID operates amidst a crowded sector, competing primarily with other PPIs such as omeprazole (Prilosec), esomeprazole (Nexium), pantoprazole (Protonix), and newer agents like vonoprazan. Its unique formulation combining omeprazole with sodium bicarbonate offers an advantage by reducing the time to symptom relief and possibly enhancing bioavailability. However, patent expirations and generic proliferation pose risks.

Patent and Exclusivity Considerations

Original ZEGERID formulations held patents protecting its unique delivery system; however, these patents have now largely expired. Generic versions of omeprazole dominate OTC sales, significantly reducing ZEGERID’s market share in some segments. The loss of regulatory exclusivity tempers revenue growth but opens opportunities for strategic repositioning.

Regulatory and Reimbursement Environment

While prescription ZEGERID benefits from physician oversight, OTC sales are regulated by agencies like the FDA, with reclassification potential influencing market access. Reimbursement policies favor less costly OTC options, but insurers typically do not cover OTC drugs, limiting direct reimbursement revenue.

Distribution Channels and Market Penetration

Distribution through pharmacies, healthcare providers, and online platforms impacted sales. E-commerce channels have gained prominence, especially during the COVID-19 pandemic, expanding accessibility. Strategic partnerships with pharmacy chains and online retailers contribute to growth.


Financial Trajectory and Revenue Outlook

Historical Performance

Historically, ZEGERID generated peak annual revenues exceeding USD 300 million before patent expiry and market saturation shifted sales toward generics. Post-2010, revenues declined due to increased generic competition, with a substantial dip following patent losses around 2013–2015. (Source: EvaluatePharma)

Current Revenue Streams

Currently, ZEGERID’s revenues are primarily derived from:

  • Prescription formulations: Limited to specific indications, with sales influenced by physician prescribing habits.
  • OTC formulations: Dominant segment, with sustained growth owing to OTC market expansion.
  • Strategic licensing and co-marketing agreements: Enhancing distribution reach.

Future Revenue Projections

The outlook hinges on several factors:

  • Reformulation and innovation: Development of new formulations or combination therapies can rejuvenate interest.
  • Regulatory reclassification: Potential switch from prescription to OTC status for specific indications could revitalize sales.
  • Market penetration: Expanding into emerging markets with high GERD prevalence could boost revenues.
  • Market share shifts: Competitor launches and generic entry pose ongoing threats.

Forecast models suggest that, absent significant innovation, ZEGERID’s revenues are expected to stabilize or decline modestly over the next 3–5 years. However, targeted strategic initiatives could foster slight growth in select segments.


Key Market Trends Impacting ZEGERID's Financial Outlook

  • Growing OTC Acidity Therapy Market: As consumers seek quick, accessible solutions, OTC PPIs like ZEGERID benefit from increased self-medication trends.
  • Generic Price Competition: Volume erosion due to generics pressures margins.
  • Innovation and Biosimilar Entry: Continued development of novel acid suppression agents, such as potassium-competitive acid blockers (P-CABs), challenge existing PPIs.
  • Digital Health Integration: Telemedicine and online pharmacies facilitate broader, immediate access, influencing pharmacy revenues.

Strategic Positioning and Growth Opportunities

To enhance financial performance, ZEGERID’s stakeholders should consider:

  • Product differentiation: Emphasize rapid relief and unique formulation benefits.
  • Market expansion: Target emerging economies with rising GERD incidence.
  • Extended indications and formulations: Explore new therapeutic claims, including maintenance therapy or combination products.
  • Re-optimization of marketing strategies: Leverage digital platforms and direct-to-consumer marketing.

Risks and Challenges

  • Patent expiries and generic competition threaten revenue streams.
  • Regulatory hurdles and delays in reclassification or approval of new formulations.
  • Market saturation in mature regions diminishes growth potential.
  • Evolving scientific landscape favoring new classes of acid suppressants over traditional PPIs.

Conclusion

ZEGERID's financial trajectory reflects a typical lifecycle pattern of pioneering drugs facing patent expiration and robust generic competition. While current revenues are sustained by OTC accessibility and niche prescription markets, future growth prospects depend heavily on strategic innovation, market expansion, and regulatory navigation. Its position within a highly competitive, rapidly evolving market underscores the importance of adaptive strategies to maximize value.


Key Takeaways

  • The global GERD market's upward trend offers growth potential, yet ZEGERID’s revenues face pressure from generics.
  • Expiration of patents and increased competition necessitate innovation and market differentiation.
  • OTC sales remain the primary revenue driver, with online distribution channels expanding reach.
  • Future growth hinges on regulatory reclassification, geographic expansion, and product development.
  • Strategic responses must address market saturation, competitive threats, and emerging therapies.

FAQs

Q1: What are the main factors impacting ZEGERID's market share?
A1: Patent expirations, the proliferation of generic omeprazole, and emerging new acid suppression therapies significantly impact ZEGERID’s market share.

Q2: How does the OTC status influence ZEGERID’s revenue potential?
A2: OTC availability broadens consumer access, fueling sales volume. However, it limits pricing power and reimbursement opportunities, constraining revenue growth.

Q3: What are the key competitive advantages of ZEGERID?
A3: Its unique formulation combining omeprazole with sodium bicarbonate offers rapid symptom relief, which can differentiate it from other PPIs.

Q4: Which markets present the greatest growth opportunities for ZEGERID?
A4: Emerging markets with rising GERD prevalence and limited access to prescription medications offer significant growth potential.

Q5: How might future regulatory changes affect ZEGERID’s commercial prospects?
A5: Reclassification to OTC for additional indications could expand sales, while delays or denials could restrict market access and revenue prospects.


References

[1] Grand View Research. "Gastroesophageal Reflux Disease Market Size & Trends." 2022.
[2] EvaluatePharma. "Global Oncology and Gastrointestinal Therapeutics Revenue Trends." 2021.
[3] FDA. "Guidance on OTC Proton Pump Inhibitors." 2020.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.